Evidence Level
Monolaurin research is predominantly in vitro and animal studies, with limited human clinical trials. Lieberman et al. (2006) conducted a comprehensive review of monolaurin's antimicrobial spectrum, confirming activity against a broad range of enveloped viruses and gram-positive bacteria. Schlievert and Peterson (2012) demonstrated monolaurin's ability to inhibit Staphylococcus aureus biofilm formation and toxin production at concentrations achievable with oral supplementation. The antimicrobial mechanism — physical disruption of lipid membranes — is well-characterized and provides a resistance-proof mode of action that is distinct from antibiotics. While more human clinical trials are needed, the strong in vitro data and excellent safety profile support its use as an immune support supplement.